The elevated expression of EEF1A, a binding partner of TSPY, could potentially exacerbate the cell proliferative properties of TSPY and increase the susceptibility of affected cells in oncogenic initiation and/or progression in prostate cancer. Here, EEF1A1 is linked to prostate carcinoma.